Cargando…
APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study
RATIONALE & OBJECTIVE: Apolipoprotein L1 (APOL1) high-risk variants are associated with an increased risk for chronic kidney disease (CKD) among African Americans. Less is known regarding the risk for the development of CKD and kidney failure (end-stage kidney disease [ESKD]) among African Ameri...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664705/ https://www.ncbi.nlm.nih.gov/pubmed/34939005 http://dx.doi.org/10.1016/j.xkme.2021.05.004 |
_version_ | 1784613900065439744 |
---|---|
author | Young, Bessie A. Wilson, James G. Reiner, Alex Kestenbaum, Bryan Franceschini, Nora Bansal, Nisha Correa, Adolfo Himmelfarb, Jonathan Katz, Ronit |
author_facet | Young, Bessie A. Wilson, James G. Reiner, Alex Kestenbaum, Bryan Franceschini, Nora Bansal, Nisha Correa, Adolfo Himmelfarb, Jonathan Katz, Ronit |
author_sort | Young, Bessie A. |
collection | PubMed |
description | RATIONALE & OBJECTIVE: Apolipoprotein L1 (APOL1) high-risk variants are associated with an increased risk for chronic kidney disease (CKD) among African Americans. Less is known regarding the risk for the development of CKD and kidney failure (end-stage kidney disease [ESKD]) among African Americans with only 1 APOL1 risk variant or whether the risk is modified by sickle cell trait. STUDY DESIGN: The Jackson Heart Study is a community-based longitudinal cohort study. SETTING & PARTICIPANTS: Self-reported African Americans in the Jackson Heart Study (n = 5,306). EXPOSURES: APOL1 G1 and G2 genotypes and sickle cell trait. OUTCOMES: Incident CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m(2)), albuminuria (urinary albumin-creatinine ratio ≥ 30 mg/g), continuous and rapid kidney function decline (≥30% decline), and incident ESKD. ANALYTICAL APPROACH: Multivariable linear and logistic regression, and Cox proportional hazards models adjusted for age, sex, hypertension, diabetes, ancestry informative markers, and sickle cell trait. RESULTS: Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 APOL1 risk variants. Sickle cell trait was present in 8.5%. Compared with participants with zero APOL1 risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57), continuous decline (β = −1.90; 95% CI, −3.35 to −0.45), and rapid kidney function decline (OR, 2.21; 95% CI, 1.22 to 4.00) after adjustment for sickle cell trait, with similar results after adjustment for ancestry informative markers. Having 1 APOL1 risk variant was not associated with CKD outcomes and there was no interaction of APOL1 with sickle cell trait. LIMITATIONS: Single-site recruitment of African American individuals with APOL1 and sickle cell trait. CONCLUSIONS: The presence of 1 APOL1 risk allele was not associated with increased risk for CKD outcomes, whereas 2 risk alleles were associated with incident albuminuria, CKD, ESKD, and rapid and continuous kidney function decline. Additional studies are needed to determine factors that might alter the risk for adverse kidney outcomes among individuals with high-risk APOL1 genotypes. |
format | Online Article Text |
id | pubmed-8664705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86647052021-12-21 APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study Young, Bessie A. Wilson, James G. Reiner, Alex Kestenbaum, Bryan Franceschini, Nora Bansal, Nisha Correa, Adolfo Himmelfarb, Jonathan Katz, Ronit Kidney Med Original Research RATIONALE & OBJECTIVE: Apolipoprotein L1 (APOL1) high-risk variants are associated with an increased risk for chronic kidney disease (CKD) among African Americans. Less is known regarding the risk for the development of CKD and kidney failure (end-stage kidney disease [ESKD]) among African Americans with only 1 APOL1 risk variant or whether the risk is modified by sickle cell trait. STUDY DESIGN: The Jackson Heart Study is a community-based longitudinal cohort study. SETTING & PARTICIPANTS: Self-reported African Americans in the Jackson Heart Study (n = 5,306). EXPOSURES: APOL1 G1 and G2 genotypes and sickle cell trait. OUTCOMES: Incident CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m(2)), albuminuria (urinary albumin-creatinine ratio ≥ 30 mg/g), continuous and rapid kidney function decline (≥30% decline), and incident ESKD. ANALYTICAL APPROACH: Multivariable linear and logistic regression, and Cox proportional hazards models adjusted for age, sex, hypertension, diabetes, ancestry informative markers, and sickle cell trait. RESULTS: Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 APOL1 risk variants. Sickle cell trait was present in 8.5%. Compared with participants with zero APOL1 risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57), continuous decline (β = −1.90; 95% CI, −3.35 to −0.45), and rapid kidney function decline (OR, 2.21; 95% CI, 1.22 to 4.00) after adjustment for sickle cell trait, with similar results after adjustment for ancestry informative markers. Having 1 APOL1 risk variant was not associated with CKD outcomes and there was no interaction of APOL1 with sickle cell trait. LIMITATIONS: Single-site recruitment of African American individuals with APOL1 and sickle cell trait. CONCLUSIONS: The presence of 1 APOL1 risk allele was not associated with increased risk for CKD outcomes, whereas 2 risk alleles were associated with incident albuminuria, CKD, ESKD, and rapid and continuous kidney function decline. Additional studies are needed to determine factors that might alter the risk for adverse kidney outcomes among individuals with high-risk APOL1 genotypes. Elsevier 2021-07-15 /pmc/articles/PMC8664705/ /pubmed/34939005 http://dx.doi.org/10.1016/j.xkme.2021.05.004 Text en © 2021 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Young, Bessie A. Wilson, James G. Reiner, Alex Kestenbaum, Bryan Franceschini, Nora Bansal, Nisha Correa, Adolfo Himmelfarb, Jonathan Katz, Ronit APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study |
title | APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study |
title_full | APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study |
title_fullStr | APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study |
title_full_unstemmed | APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study |
title_short | APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study |
title_sort | apol1, sickle cell trait, and ckd in the jackson heart study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664705/ https://www.ncbi.nlm.nih.gov/pubmed/34939005 http://dx.doi.org/10.1016/j.xkme.2021.05.004 |
work_keys_str_mv | AT youngbessiea apol1sicklecelltraitandckdinthejacksonheartstudy AT wilsonjamesg apol1sicklecelltraitandckdinthejacksonheartstudy AT reineralex apol1sicklecelltraitandckdinthejacksonheartstudy AT kestenbaumbryan apol1sicklecelltraitandckdinthejacksonheartstudy AT franceschininora apol1sicklecelltraitandckdinthejacksonheartstudy AT bansalnisha apol1sicklecelltraitandckdinthejacksonheartstudy AT correaadolfo apol1sicklecelltraitandckdinthejacksonheartstudy AT himmelfarbjonathan apol1sicklecelltraitandckdinthejacksonheartstudy AT katzronit apol1sicklecelltraitandckdinthejacksonheartstudy |